TGF-β and Hepatocellular Carcinoma: When A Friend Becomes An Enemy

Marco Arrese, Alejandra Hernandez, Luis Astete, Lisbell Estrada, Claudio Cabello-Verrugio, Daniel Cabrera

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

8 Citas (Scopus)


Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide accounting for more than 700 thousand deaths per year. Most of the HCC develops in a cirrhotic liver, a microenvironment where fibrotic tissue replaces parenchymal cells. Thus, there is a close connection between fibrosis and HCC development. Understanding the cellular and molecular mechanisms involved in this process is a crucial step to advance in novel therapeutic or pharmacological strategies to prevent or improve the course of this malignancy. A key molecular player capable of modulating cell growth and fibrosis is the Transforming Growth Factor-beta (TGF-β). Interestingly, TGF-β seems to act like a switch, since it has dual and opposite roles during early and late phases of cancer development. Therefore to develop therapies that target TGF-β signaling pathway for HCC treatment is important to understand the underlying pathogenetic mechanisms at play with special emphasis in the crosstalk between TGF-β and other signaling pathways. In recent years, a plethora of TGR-β have been developed and some of them are under clinical investigations for testing in patients with advanced HCC. In this review, we summarize recent knowledge about the role of TGF-β signaling pathway in HCC progression.

Idioma originalInglés
Páginas (desde-hasta)1172-1179
Número de páginas8
PublicaciónCurrent protein & peptide science
EstadoPublicada - 1 ene 2018

Áreas temáticas de ASJC Scopus

  • Bioquímica
  • Biología molecular
  • Biología celular


Profundice en los temas de investigación de 'TGF-β and Hepatocellular Carcinoma: When A Friend Becomes An Enemy'. En conjunto forman una huella única.

Citar esto